Dizal Pharmaceutical Co Ltd. Class A
SSSE:68819263.34
CNY
+3.59
(+6.01%)
Dizal Pharmaceutical Co Ltd. Class A
SSE:688192
(Shanghai Stock Exchange)
Recent
price
63.34
P/E
ratio
- -
div
yld
0.11%
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Dizal Pharmaceutical Co., Ltd. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes differentiated small-molecule targeted therapeutics for the treatment of malignant tumors and immunological diseases. Founded in 2017 as an innovation-driven enterprise originating from AstraZeneca Innovation Center China and the Chinese Future Industry Investment Fund, the company is headquartered in Wuxi, Jiangsu Province, China, with major research, clinical, and administrative operations in Shanghai, as well as clinical development capabilities in the United States. The company operates in the biotechnology and pharmaceutical sectors, delivering specialized precision medicines across oncology, hematology, and autoimmune therapeutic areas. The company’s core commercial products and investigational pipeline comprise: ZEGFROVY (sunvozertinib, marketed domestically as Shuwozhe), an oral, potent, irreversible epidermal growth factor receptor tyrosine kinase inhibitor approved for locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations; Gao Ruizhe (golidocitinib), an oral, first-in-class, highly selective Janus kinase 1 inhibitor approved for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma; DZD6008, a next-generation, blood-brain barrier-penetrant EGFR inhibitor in clinical development for non-small cell lung cancer progressing after third-generation EGFR inhibitor therapy; birelentinib (DZD8586), an oral, non-covalent dual inhibitor of Bruton tyrosine kinase and LYN kinase targeting B-cell non-Hodgkin lymphomas, chronic lymphocytic leukemia, and small lymphocytic lymphoma; DZD1516, a selective, blood-brain barrier-penetrant HER2 inhibitor evaluated for HER2-positive breast cancer brain metastases; DZD2269, an adenosine A2a receptor antagonist targeting solid tumors; GW-5282, an EZH1/EZH2 dual inhibitor for hematological malignancies; and DZD0095, a monocarboxylate transporter 4 inhibitor. In recent strategic developments, Dizal entered into an exclusive global licensing collaboration agreement with AstraZeneca for ZEGFROVY (sunvozertinib) in a transaction valued at up to 1.5 billion USD across upfront consideration, development milestones, sales milestones, and tiered royalties; broadened its commercial footprint internationally following regulatory approvals in China and the United States Food and Drug Administration clearance for sunvozertinib; demonstrated superior clinical outcomes in first-line non-small cell lung cancer in Phase 3 pivotal trials; and accelerated the commercialization, hospital distribution, and market penetration of golidocitinib for peripheral T-cell lymphoma patients.